Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Mutant p53 mediates survival of breast cancer cells.

Lim LY, Vidnovic N, Ellisen LW, Leong CO.

Br J Cancer. 2009 Nov 3;101(9):1606-12. doi: 10.1038/sj.bjc.6605335. Epub 2009 Sep 22.

2.

Radioisotopic localization of (90)Yttrium-ibritumomab tiuxetan in patients with CD20+ non-Hodgkin's lymphoma.

Jacobs SA, Harrison AM, Swerdlow SH, Foon KA, Avril N, Vidnovic N, Joyce J, DeMonaco N, McCarty KS Jr.

Mol Imaging Biol. 2009 Jan-Feb;11(1):39-45. doi: 10.1007/s11307-008-0170-3. Epub 2008 Sep 5.

PMID:
18773247
3.

The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers.

Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW.

J Clin Invest. 2007 May;117(5):1370-80. Epub 2007 Apr 19.

4.

Durable remission of HIV-negative, Kaposi's sarcoma herpes virus-associated multicentric Castleman disease in patient with rheumatoid arthritis treated with methotrexate.

Jacobs SA, Vidnovic N, Patel H, Soma LA, Chang Y, Bass N, Swerdlow SH.

Clin Rheumatol. 2007 Jul;26(7):1148-50. Epub 2006 Jul 6.

PMID:
16572284
5.

Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy.

Jacobs SA, Vidnovic N, Joyce J, McCook B, Torok F, Avril N.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7146s-7150s.

Supplemental Content

Loading ...
Support Center